Roche, BioNTech post 'low' response rate in cancer vaccine trial

Roche, BioNTech post 'low' response rate in cancer vaccine trial

Source: 
Fierce Biotech
snippet: 

A phase 1b trial of a personalized cancer vaccine in development at Roche and BioNTech has chalked up a “low” response rate. Nine of the 108 evaluable solid tumor patients responded when given the vaccine in combination with Tecentriq, although researchers pointed to immune response results to support continued study in other populations.